BioLytical

The Florida Department of Health, Bureau of Communicable Disease, HIV/AIDS Section, is seeking to acquire INSTI HIV-1/HIV-2 Antibody Tests from BioLytical Laboratories Inc. under a single-source procurement authorized by Chapter 60A-1.045, F.A.C., to enable earlier detection of HIV infection by identifying antibodies up to nine days sooner than the Western Blot test, thereby facilitating immediate medical intervention and reducing disease transmission. The selected test is the only FDA-approved rapid diagnostic tool capable of delivering results in under 60 seconds and is designated under NAICS code 41116164 for laboratory proficiency assessment test kits. The acquisition is limited to a one-year term with an estimated contract value of $75,000, and performance is required entirely within the state of Florida. The solicitation, identified as EXP2684, was posted on June 16, 2026, with responses due by July 10, 2026, and no competitive evaluation factors or detailed technical specifications are applicable due to the sole-source nature of the procurement under state statute. All inquiries must be directed to Yasemin Sulker at the Florida Department of Health in Tallahassee, with no additional packaging, inspection, delivery, or administrative requirements specified beyond the core procurement justification.